Boston Scientific (NYSE:BSX) is a potential acquirer for mitral valve maker Neovasc (NSDQ:NVCN), according to JMP Securities analyst John Gillings, after agreeing to a $435 million deal for aortic valve maker Symetis that doesn’t include its Middle Peak Medical mitral valve assets. Although the all-cash Symetis deal adds the market-ready Acurate transcatheter aortic valve implant to Boston Scientific’s […]
Mvalve
Boston Scientific ups stake in stealthy MValve and its TMVI docking tech
Boston Scientific (NYSE:BSX) said today that it boosted its stake in stealthy Israeli medical device company MValve, which is developing “docking” technology for transcatheter mitral valve implants. Marlborough, Mass.-based Boston Scientific put $15 million into MValve last year in a deal that included a $200 million buyout option. MValve, which is based in San Diego and […]